| abstract |
Methods are provided for utilizing omega-3 fatty acids, or a combination of dyslipidemic agent and omega-3 fatty acids, for the reduction of lipoprotein associated phospholipase A2 (Lp-PLA2) levels. The methods are especial useful in the treatment of patients with primary hypercholesterolemia or hypertriglyceridemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for th prevention or reduction of major adverse cardiovascular events (MACE), major coronary events (MCE), particularly myocardial infarction (Ml), revascularizations and ischemic stroke. |